Analysts split on Biogen's potential sale

11/14/2007 | Boston Globe (tiered subscription model), The

A biotech analyst said the potential sale of Biogen Idec to a major drugmaker could reach up to $30 billion if buyers remain positive on the future of its multiple sclerosis drug Tysabri in the market. However, some stock analysts believe the company might not be able to find a buyer due to competition and Biogen's drug-development deals with Elan Corp. and Genentech.

View Full Article in:

Boston Globe (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC